Biogen Pays $124 Million to Develop Gene-Based Therapies
On Thursday, Biogen Inc. will enter into the area of eye-disease treatment by paying Applied Genetic Technologies Corp. (AGTC) about $124 million for licensing its products, and co
On Thursday, Biogen Inc. will enter into the area of eye-disease treatment by paying Applied Genetic Technologies Corp. (AGTC) about $124 million for licensing its products, and co